Lupin, Dr Reddy’s Laboratories, Cadila Healthcare, Torrent Pharmaceuticals, Ipca Laboratories, Cipla and Wockhardt are up 1-5% on the National Stock Exchange (NSE).
CNX Pharma index, gauge of pharmaceutical companies, the largest gainer among sectoral indices, was up 1.3% at 9,323 at 1415 hours. The index touched a record high of 9,339 during intra-day trades. The benchmark CNX Nifty however, trading flat at 7,749.
Lupin, the largest gainer among pharma pack, has surged 5% to Rs 1,175, also its new high, after reporting a better-than-expected 56% year-on-year jump in net profit at Rs 625 crore for the quarter ended June 2014 (Q1), on back of strong growth in the US and in India. The drug maker had profit of Rs 401 crore in the same quarter last fiscal. Net sales grew 36% to Rs 3,284crore on yoy basis, Lupin said in a statement. Analysts on an average had expected profit of Rs 512 crore on sales of Rs 3,116 crore.
Dr Reddy’s Laboratories too, gained 3% to Rs 2,840 on reporting 52% yoy jump in consolidated net profit at Rs 550 crore on back of 24% growth in net sales at Rs 3,518 crore for the quarter ended June 2014. Gross profit margins improved by over 600 basis points to 59.3% against 52.8% in the same quarter last fiscal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)